sotagliflozin
Sponsor Lexicon Pharmaceuticals, INC. · listed as LXRX
sotagliflozin is a drug asset sponsored by Lexicon Pharmaceuticals, INC., listed as LXRX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 2027 (month precision, medium confidence), tied to trial NCT06481891. That trial is in Phase 3 and currently active not recruiting, studying Obstructive Cardiomyopathy, Hypertrophic. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for sotagliflozin in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06481891 catalyst | Phase 3 | Active, not recruiting | 2027-01 | Experimental | Lexicon Pharmaceuticals | Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy |
| NCT06217302 | Phase 3 | Recruiting | 2028-12 | Active comparator | Alessandro Doria | Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More LXRX catalysts